Ezose Sciences Enters Glycomics Research Agreement with Kyowa Hakko Kirin
News Jan 29, 2013
Ezose Sciences Inc. announced that it has entered a research agreement with Kyowa Hakko Kirin Co. Ltd. to collaborate on glycomics studies using Ezose’s proprietary GlycanMap® technology platform.
Under terms of the research agreement, Kyowa Hakko Kirin will fund several glycan-biomarker and other discovery projects, with an option for further research and development. Other details of the agreement were not disclosed.
“We look forward to putting our unique glycan-analysis capabilities to the service of the specific research interests of Kyowa Hakko Kirin,” said Hidehisa Asada, Ph.D., Vice President, Research & Development of Ezose. “As the structure of our collaboration anticipates, the research will seek new discoveries that enable novel therapeutic strategies and sustain the flow of new products to market.”
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE